Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
10:30am, Tuesday, 12'th Dec 2023
Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. SAN DIEGO , Dec. 12, 2023 /PRNewswire/ --
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakth
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results f
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
08:32am, Thursday, 09'th Nov 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
09:02pm, Wednesday, 08'th Nov 2023
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
04:02pm, Wednesday, 08'th Nov 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sa
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical stren
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
08:34am, Tuesday, 31'st Oct 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference c
ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript
08:32pm, Wednesday, 09'th Aug 2023
ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Bria
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
08:02am, Wednesday, 02'nd Aug 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, Au
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
08:34am, Thursday, 11'th May 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, a
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
ChromaDex (CDXC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.11 per share a year ago.
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
08:32am, Tuesday, 02'nd May 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference c
ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript
09:42pm, Wednesday, 08'th Mar 2023
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive O
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
07:33pm, Wednesday, 08'th Mar 2023
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
